The Cytotoxic Natural Product Vioprolide A Targets Nucleolar Protein 14, Which Is Essential for Ribosome Biogenesis

Volker C. Kirsch*, Christina Orgler*, Simone Braig, Irmela Jeremias, David Auerbach, Rolf Müller, Angelika M. Vollmar,* and Stephan A. Sieber*

Abstract: Novel targets are needed for treatment of devastating diseases such as cancer. For decades, natural products have guided innovative therapies by addressing diverse pathways. Inspired by the potent cytotoxic bioactivity of myxobacterial vioprolides A–D, we performed in-depth studies on their mode of action. Based on its prominent potency against human acute lymphoblastic leukemia (ALL) cells, we conducted thermal proteome profiling (TPP) and deciphered the target proteins of the most active derivative vioprolide A (VioA) in Jurkat cells. Nucleolar protein 14 (NOP14), which is essential in ribosome biogenesis, was confirmed as a specific target of VioA by a suite of proteomic and biological follow-up experiments. Given its activity against ALL cells compared to healthy lymphocytes, VioA exhibits unique therapeutic potential for anticancer therapy through a novel mode of action.

Natural products display a rich source of bioactive molecules selected by evolution to target distinct molecular pathways in eukaryotic and prokaryotic cells. One of the preeminent producers of a wide range of bioactive secondary metabolites are myxobacteria. In 1996, the isolation of peptolides vioprolides A–D (Figure 1A) was reported from Cystobacter violaceus and detailed studies on their biosynthesis have recently been performed. Despite their antifungal and anticancer activities in the low nanomolar range, as well as immunomodulatory activity in micromolar concentrations, no molecular target elucidation has been reported up to date.

Despite the wealth of target identification methods available, including activity-based protein profiling (ABPP) and thermal proteome profiling (TPP), numer-
ous natural products still lack functional characterization. This information is needed in order to decipher novel and unprecedented modes of action in cancer cells, where drug resistance, therapeutic failure, or relapse require new targets and cellular pathways with high specificity towards tumor cells.\[10\]

By applying diverse proteomic and biochemical methods we investigated the cellular mechanism of vioprolide A (VioA) in Jurkat cancer cells and recovered nucleolar protein 14 (NOP14), which is essential for ribosome biogenesis, to be a specific target.

Prior to target-identification studies, we ranked vioprolide A–D potencies in the acute lymphoblastic leukemia (ALL) cell line Jurkat to select the most potent growth inhibitory compound for subsequent mode of action analysis. VioA exhibited the highest antiproliferative activity, with a half maximal inhibitory concentration (IC\(_{50}\)) of 4 nM (Figure 1B). In line with a previous report,\[3\] the vioprolides showed significant differences in bioactivity, thus demonstrating that the structural composition of the N-heterocycles is crucial for potency (Figure 1A).

Moreover, VioA displayed low nanomolar IC\(_{50}\) values in different cell lines, thus illustrating its broad potency (Figure 2A, Figure S1 in the Supporting Information). To analyze whether enhanced cell death rates contribute to diminished proliferative capacity of VioA-treated cancer cells, apoptosis assays were performed. VioA exhibited an EC\(_{50}\) of 15.8 and 28.9 nM in CEM and Jurkat cells, respectively, signifying a high apoptosis rate in acute lymphoblastic leukemia (ALL) cells, compared to the acute myeloid leukemia (AML) cell line HL-60 (EC\(_{50}\): 88.1 nM), as well as HeLa (EC\(_{50}\): 134 nM) and T24 cells (EC\(_{50}\): n.a.; Figure 2B). This was confirmed by the extent of caspase-3 activation and PARP cleavage, as analyzed by western blotting (Figure S2). Mechanistic studies on apoptosis induction revealed intrinsic apoptotic cell death triggered by VioA (Figure S3, see discussion in the Supporting Information). Moreover, cell-cycle progression in Jurkat cells treated with VioA showed a significant decrease in cells in S-phase, as measured by flow cytometry analysis (Figure 2C).

To confirm the potency of VioA in ALL and to analyze its putative therapeutic relevance, the compound was tested in ALL patient-derived xenograft (PDX) cells. VioA-treated ALL samples of diverse background (Table S1) exhibited an increased apoptosis rate after 24 h treatment, as shown by flow cytometry (Figure 2D). Notably, peripheral blood mononuclear cells (PBMCs) of healthy donors barely responded to VioA compared to PDX samples (Figure 2D), thus clearly demonstrating that VioA exhibits auspicious antileukemic properties.

**Figure 2.** Anticancer effects of VioA. A) Inhibition of proliferation and corresponding IC\(_{50}\) values were analyzed by cell titer blue assay (suspension cell lines) or crystal violet staining (adherent cell lines) after 72 h. Experiments were conducted in three independent experiments and performed in triplicates. B) Apoptosis of various cancer cell lines treated with VioA for 24 h. Percentage of apoptotic cells and corresponding EC\(_{50}\) values were determined by propidium iodide (PI) staining and flow cytometry. Data points represent mean ± SEM of three independent experiments performed in triplicate. C) Cell-cycle analysis of VioA-treated Jurkat cells (24 h) was performed by PI staining and flow cytometry analysis. Bars show the mean ± SEM of three independent experiments performed in triplicate, one-way ANOVA, Dunnett’s test, *p < 0.033, **p < 0.002, ***p < 0.001. D) ALL PDX cells and PBMCs treated with VioA for 24 h. Percentage of apoptotic cells was determined by flow cytometry and specific apoptosis was calculated relative to DMSO control. Data points represent mean ± SEM of independent experiments performed in triplicates (PDX cells: n = 2, PBMCs: n = 3), one-way ANOVA Dunnett’s test, *p < 0.033, ***p < 0.001.
To rationalize the molecular mechanism underlying the potency of VioA in ALL, we performed target identification through affinity-based protein profiling (AfBPP). The VioA scaffold was functionalized with a photocrosslinker and a biorthogonal linker to yield the probe VioA-P (Scheme S1). Although the antiproliferative potency of the probe against Jurkat cells only dropped by 4-fold (Figure S4), in situ labeling with concentrations ranging from 0.5 μM to 2 μM revealed known background binders among the enriched proteins, but no clear target (Figure S5). Since the modification with the minimal linker could have perturbed the binding properties to the dedicated target(s) and the probe ester bond suffered from limited stability (Figure S6), TPP was selected as an alternative modification-free strategy.

Jurkat cells were incubated in situ with VioA (1 μM) or DMSO and subsequently exposed to a range of temperatures (37°C–67°C). Cells were lysed and soluble proteins were isolated by ultracentrifugation, trypically digested, and labeled using isobaric tandem mass tag labels (TMT). Respectively labeled samples were combined, subjected to hydrophilic-interaction chromatography (HILIC) fractionation and finally analyzed by LC-MS/MS (Figure 3A). Temperature shifts were calculated from two replicates of VioA versus DMSO treatment and visualized after filtering (Figure 3B; see the Supporting Information for filtering criteria). 67 proteins revealed a minimum temperature shift of 1°C in both VioA- versus DMSO-treated replicates and were manually inspected for proper melting curves. Six proteins (blue dots Figure 3B; for melting curves, see Figure S7, Table S2) passed additional significance thresholds (see the Supporting Information). Among these, U2 snRNP-associated SURP motif-containing protein (U2SURP) and nucleolar protein 14 (NOP14) were highly stabilized upon VioA treatment (Figure 3B,C). We selected these two major hits for in-depth validation. U2SURP is a spliceosomal factor and NOP14 (which showed the highest shift) is crucial for 40S ribosome subunit formation as well as maturation of 18S rRNA.

U2SURP was excluded as a potential target of VioA because splicing was not affected in VioA-treated cells, as shown by dual luciferase splicing reporter assay (Figure S8). NOP14 plays a crucial role in the initial steps of ribosome biogenesis, namely, the formation of the small subunit processome (SSU processome), an early stage of the formation of the small ribosomal subunit (40S). This processing is enhanced in cancer cells due to the high demand for continuous ribosome production for their extensive growth. In eukaryotes, ribosome biogenesis takes place in the nucleoli that contain genes encoding for ribosomal RNAs (rRNAs), which build the nucleic acid backbone of the ribosome. Interestingly, NOP14 siRNA knockdown cells (knockdown confirmation shown in Figure S9) as well as VioA-treated cells displayed reduced rRNA levels in nucleoli, as demonstrated by 5-FU immunostaining (Figure 4A,B). Actinomycin D (ActD), which inhibits Pol I transcription, served as positive control. rDNA transcription is necessary for the formation of nucleoli, whereas perturbations of the transcriptional machinery lead to their disassembly. Consistently, ActD treatment led to displacement of NOP14 in the whole nucleus due to nucleolar disruption, whereas VioA treatment did not alter the localization of NOP14. Based on these results, VioA obviously does not interfere with ribosome biogenesis at the level of transcription (Figure 4C). Importantly, knockdown of NOP14 impairs cancer-cell proliferation (Figure 4D) as shown before for VioA (Figure 1B, Figure 2A).

Figure 3. Target identification of VioA in Jurkat cells using thermal proteome profiling. A) Schematic workflow of the thermal proteome profiling experiment. Living Jurkat cells were treated with 1 μM VioA or DMSO for 1 hour. Subsequently, aliquots were incubated at 9 different temperatures (37°C–67°C), centrifuged, and the proteins digested in supernatant. After TMT labeling and HILIC fractionation, the samples were analyzed by mass spectrometry. B) Scatterplot of ΔTm shifts determined from two biological replicates of VioA vs. DMSO treatment. Melting-point shifts passing all significance criteria (see Supporting Information) are shown in blue. Data was preprocessed using MaxQuant and thermal-response curve fitting as well as melting-point calculations were carried out using the TPP R package. C) Thermal-response curves and calculated melting points (asterisks) for NOP14 and U2SURP proteins of VioA-treated (orange) and DMSO-treated (gray) cells. Two biological replicates are shown.
Various protein–protein interactions with NOP14 are essential for a functional ribosome biogenesis machinery in yeast.\[13,17\] Thus, we focused on unravelling the interactome of NOP14 through MS-based co-immunoprecipitation (co-IP) experiments. Co-IP (with an immobilized anti-NOP14 antibody) was carried out in presence of a DSSO crosslinker to enable the trapping of transient binding partners as applied previously (Figure 5A).\[18\] Analysis of pulled-down proteins by LC–MS/MS identified several significantly enriched proteins (Table S3) compared to the isotype control co-IP in Jurkat cells, among others, nucleolar complex protein 4 homolog (NOC4L) and ribosomal RNA small subunit methyltransferase NEP1 (EMG1). In order to identify VioA-sensitive interactions of NOP14, the co-IP experiment was repeated with compound treatment for 24 hours prior to in situ DSSO crosslinking (Figure S10, Table S4). Treatment with VioA led to the depletion of various proteins enriched in non-treated co-IP experiments (Table S4). Since it is known that interaction of NOP14 with both NOC4L and EMG1 is essential for proper maturation of 18S rRNA and 40S assembly and export,\[13,19\] we investigated the influence of VioA treatment on the interplay of those proteins.

Remarkably, MS-based and western blot based co-IP experiments revealed that VioA treatment led to a selective loss of interaction between NOP14 and EMG1, whereas the NOP14–NOC4L association remained unperturbed (Figure 5C,D). Of note, expression levels of neither NOC4L nor EMG1 were affected by VioA (Figure 5E).

In yeast, EMG1 is involved in the modification of uridine 1191 of the 18S rRNA. Its catalytic activity is not essential for ribosome biogenesis, however the presence of the protein within the 90S pre-ribosome is inevitably required.\[20\] Nucleolar localization of NOP14 depends on binding to NOC4L.\[22\] This interaction is not disturbed by VioA, hence, NOP14 remains in the nucleolus upon VioA treatment. However, since the physical interaction of NOP14 with EMG1 is required for nuclear localization of EMG1,\[13\] impaired binding of those two proteins upon VioA treatment led to a distribution of EMG1 in the entire cell in comparison to control cells, where EMG1 is mainly located in the nucleus (Figure 5F).

In conclusion, vioprolides represent a unique class of natural products with potent bioactivity towards cancer cells in the nanomolar range. Using TPP, we identified NOP14, which is involved in ribosome biogenesis, as an unprecedented interaction partner of VioA. NOP14 plays a key role in the assembly of the small ribosomal subunit and in fact, VioA is the first natural product reported that addresses this crucial pathway. PBMCs showed low response to VioA in contrast to ALL cancer cells, thus suggesting VioA as a promising lead structure for cancer-cell targeting. Closer mechanistic studies showed that VioA alters the interaction of NOP14 with EMG1, leading to delocalization of EMG1. Our results indicate that targeting the NOP14-EMG1 interaction, and thereby ribosome biogenesis, is a promising anticancer strategy and underline the great potential of VioA as a chemical tool to study ribosomal processes as well as starting point for future drug development.
Figure 5. Co-immunoprecipitation with anti-NOP14 antibody. A) Schematic workflow of MS-based co-immunoprecipitation. Living cells were treated with 10 nM VioA or DMSO, respectively, for 24 hours. Subsequently, DSSO linker was added to covalently link protein complexes within cells. NOP14 and linked proteins were enriched using an anti-NOP14 antibody immobilized on protein A/G beads. Tryptic peptides were measured via LC-MS/MS, and analyzed using MaxQuant\cite{14} and Perseus.\cite{21} B) Volcano plot represents two-sample t-test results of anti-NOP14 co-IP compared to isotype control co-IP (n = 4). Cutoff criteria were defined as log$_2$(4-fold enrichment) enrichment factor and -log$_{10}$(t-test p-value) = 1.3 (dotted lines). NOP14 is colored in blue, NOC4L in dark grey and EMG1 in orange. C) Comparison of normalized LFQ intensities of NOP14, NOC4L and EMG1 in isotype control and anti-NOP14 co-IP samples treated with 10 nM VioA prior to co-IP after missing value imputation. D) Co-IP of NOP14 in Jurkat cells and detection of NOP14 and interactors NOC4L/EMG1 by western blot analysis. A representative experiment out of three independent experiments is shown. Bars represent mean ± SEM of three independent experiments, two-tailed unpaired Student’s t-test, ***P < 0.001. E) Western blot analysis of NOP14, NOC4L and EMG1 expression levels of Jurkat cells either treated with DMSO or 10 nM VioA for 24 h. Bars represent the mean ± SEM of three independent experiments, two-tailed unpaired Student’s t-test, ns P > 0.05. F) HeLa cells treated with VioA were co-stained for NOP14 (red) and EMG1 (green). Nuclei were stained with Hoechst 33342. Representative images out of three independent experiments performed in duplicate are shown.
The MS data have been deposited to the ProteomeX-change Consortium via the PRIDE[23] partner repository with the dataset identifier PXD015196.

Acknowledgements

This work was funded by the Deutsche Forschungsgemeinschaft (FOR1409) and the Center for Integrated Protein Science (CIPSW). We thank Mona Wolff, Katja Bäuml, Katja Gliesche, Ida Folda, Julia Blenninger and Sylvia Schnegg for technical assistance, Dr. Binje Vick for providing PDX cells and Dr. Vadim Korotkov for the supply of DSSO crosslinker. Dr. Matthias Stahl is thanked for critical proofreading of the manuscript and discussions of TPP experiments.

Conflict of interest

The authors declare no conflict of interest.

Keywords: acute lymphoblastic leukemia · natural products · quantitative proteomics · ribosomess · target identification

How to cite: Angew. Chem. Int. Ed. 2020, 59, 1595–1600

Angew. Chem. 2020, 132, 1611–1617

[1] T. Rodrigues, D. Reker, P. Schneider, G. Schneider, Nat. Chem. 2016, 8, 531–541.
[2] a) J. Herrmann, A. A. Fayad, R. Müller, Nat. Prod. Rep. 2017, 34, 135–160; b) J. Diez, J. P. Martinez, J. Mestres, F. Sasse, R. Frank, A. Meyerhans, Microb. Cell Fact. 2012, 11, 52.
[3] a) F. Yan, D. Auerbach, Y. Chai, L. Keller, Q. Tu, S. Huttel, A. Glemsr, H. A. Grab, T. Bach, Y. Zhang, R. Müller, Angew. Chem. Int. Ed. 2018, 57, 8754–8759; Angew. Chem. 2018, 130, 8890–8895; b) F. Yan, R. Müller, ACS Chem. Biol. 2019, 14, 99–105.
[4] D. Chauhan, E. Bartok, M. M. Gaidt, F. J. Bock, J. Herrmann, J. M. Seeger, P. Broz, R. Beckmann, H. Kashkar, S. W. G. Tait, R. Müller, V. Hornung, Cell Rep. 2018, 25, 2354–2368.
[5] D. Schummer, G. Hofle, E. Forche, H. Reichenbach, V. Wray, T. Domke, Liebigs Ann. 1996, 971–978.
[6] a) Y. Liu, M. P. Patricelli, B. F. Cravatt, Proc. Natl. Acad. Sci. USA 1999, 96, 14694–14699; b) A. E. Speers, G. C. Adam, B. F. Cravatt, J. Am. Chem. Soc. 2003, 125, 4686–4687; c) A. Saghatelian, N. Jessani, A. Joseph, M. Humphrey, B. F. Cravatt, Proc. Natl. Acad. Sci. USA 2004, 101, 10000–10005; d) A. E. Speers, B. F. Cravatt, Chem. Biol. 2004, 11, 533–546; e) K. T. Barglow, B. F. Cravatt, Nat. Methods 2007, 4, 822; f) A. M. Sadaghiani, S. H. L. Verhelst, M. Bogoy, Carr. Opin. Chem. Biol. 2007, 11, 20–28; g) M. J. Evans, B. F. Cravatt, Chem. Rev. 2006, 106, 5279–3301; h) D. J. Lapinsky, Bioorg. Med. Chem. 2012, 20, 6237–6247.

[7] P. P. Geurink, L. M. Prely, G. A. van der Marel, R. Bishoff, H. S. Overkleeft, Top. Curr. Chem. 2012, 324, 85–113.
[8] a) M. M. Savitski, F. B. M. Reinhard, H. Franken, T. Werner, M. F. Savitski, D. Eberhard, D. M. Molina, R. Jafari, R. B. Dovega, S. Klager, B. Kuster, P. Nordlund, M. Bantschegg, G. Drewes, Science 2014, 346, 1255784; b) A. Mateus, T. A. Maatta, M. M. Savitski, Proteome Sci. 2017, 15, 13.
[9] H. Franken, T. Mathieson, D. Chils, G. M. Sweetman, T. Werner, I. Tegel, C. Doce, S. Gade, M. Bantschegg, G. Drewes, F. B. Reinhard, W. Huber, M. M. Savitski, Nat. Protoc. 2015, 10, 1567–1593.
[10] N. Widmer, C. Bardin, E. Chatelut, A. Paci, J. Beijnen, D. Levêque, G. Veal, A. Astier, Eur. J. Cancer 2014, 50, 2020–2036.
[11] M. H. Wright, S. A. Sieber, Nat. Prod. Rep. 2016, 33, 681–708.
[12] P. Kleiner, W. Heydenreuter, M. Stahl, V. S. Korotkov, S. A. Sieber, Angew. Chem. Int. Ed. 2017, 56, 1396–1401; Angew. Chem. 2017, 129, 1417–1422.
[13] P. C. Liu, D. J. Thiele, Mol. Biol. Cell 2001, 12, 3644–3657.
[14] a) J. Cox, M. Mann, Nat. Biotechnol. 2008, 26, 1367–1372; b) S. Tyanova, T. Temu, J. Cox, Nat. Protoc. 2016, 11, 2301–2319.
[15] N. Hein, K. M. Hannan, A. J. George, E. Sanij, R. D. Hannan, Trends Mol. Med. 2013, 19, 643–654.
[16] F.-M. Boisvert, S. van Koningsbruggen, J. Navascués, A. I. Lamond, Nat. Rev. Mol. Cell Biol. 2007, 8, 574.
[17] H. Kühn, T. Hierlemeyer, J. Merl, S. Jakob, A. H. Aguissa-Touré, P. Milkreit, H. Tschochner, PLoS One 2009, 4, e6570.
[18] A. Fux, V. S. Korotkov, M. Schneider, I. Antes, S. A. Sieber, Cell Chem. Biol. 2019, 26, 48–59.
[19] P. Milkreit, D. Strauss, J. Bassler, O. Gadal, H. Kuhn, S. Schutz, N. Gas, J. Lechner, E. Hurt, H. Tschochner, J. Biol. Chem. 2003, 278, 4072–4081.
[20] N. Leulliot, M. T. Bohnsack, M. Graille, D. Tollervey, H. Van Tilburg, Nucleic Acids Res. 2008, 36, 629–639.
[21] S. Tyanova, T. Temu, P. Sinteyen, A. Carlson, M. Y. Hein, T. Geiger, M. Mann, J. Cox, Nat. Methods 2016, 13, 731–740.
[22] K. A. Bernstein, J. E. Gallagher, B. M. Mitchell, S. Granneman, S. J. Baserga, Eukaryotic Cell 2004, 3, 1619–1626.
[23] Y. Perez-Riverol, J. Bai, M. Bernal-Llinares, S. Hewapathirana, D. J. Kundu, A. Inuganti, J. Griss, G. Mayer, M. Einsenacher, E. Pérez, J. Uszkoreit, J. Pfueffer, T. Sachsenberg, S. Yilmaz, S. Tiwary, J. Cox, E. Audain, M. Walzer, A.F. Jarnuczak, T. Tement, A. Brazma, JA. Vizcaíno, Nucleic Acids Res. 2019, 47, 442–450.

Manuscript received: September 1, 2019
Revised manuscript received: October 24, 2019
Accepted manuscript online: November 28, 2019
Version of record online: December 12, 2019